Press Releases

Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference at 12:00 PM EST...

Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB rated generic version of Mycolog® II Cream (nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1...

Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB rated generic version of Exalgo® 32mg extended release tablets (hydromorphone HCl) C-II. Exalgo® 32mg extended release...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its Active Pharmaceutical Ingredient (API) business based in Israel to SK...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Stifel Healthcare Conference at 8:45 AM EST on Tuesday,...

Delivered third quarter 2017 GAAP ("reported") net sales of $1.2 billion, reported net income of $45 million and reported diluted earnings per share ("EPS") of $0.31 compared to a loss per share...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on December 19, 2017 to shareholders of record on...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter 2017 financial results on Thursday, November 9, 2017. The Company will also host a conference call...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) brought by...